BioSig Technologies, Inc. (BSGM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioSig Technologies, Inc. (BSGM) trades at $6.10 with AI Score 61/100 (Grade B+). BioSig Technologies, Inc. is a medical device company focused on enhancing intracardiac signal acquisition. Market cap: $191.13M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for BSGM: BSGM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BSGM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BSGM: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →BioSig Technologies, Inc. (BSGM) Healthcare & Pipeline Overview
BioSig Technologies, Inc. develops the PURE EP system, a signal processing platform for electrophysiology procedures, targeting the atrial fibrillation market. The company collaborates with research institutions to advance AI-driven diagnostic solutions, positioning itself in the competitive medical device landscape with a focus on real-time signal analysis.
What Is the Investment Thesis for BSGM?
BioSig Technologies operates in the electrophysiology market, with its PURE EP system designed to improve signal acquisition during cardiac ablation procedures. A key value driver is the ongoing collaboration with the Mayo Foundation to develop AI-driven diagnostic tools, potentially enhancing the PURE EP system's capabilities. Growth catalysts include expanding adoption of the PURE EP system in hospitals and electrophysiology labs, and positive results from research collaborations. Potential risks include competition from established medical device companies and the need for regulatory approvals. With a market capitalization of $191.13M and a beta of 1.82, BioSig presents a high-risk, high-reward investment profile.
Based on FMP financials and quantitative analysis
BSGM Key Highlights
- BioSig Technologies' primary product is the PURE EP system, a signal processing platform designed to improve signal acquisition during electrophysiology procedures.
- The company has a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop AI and machine learning software solutions for the PURE EP system.
- BioSig has a research agreement with the University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases.
- The company focuses on enhancing intracardiac signal acquisition and diagnostic information for atrial fibrillation procedures.
- BioSig Technologies has a market capitalization of $191.13M and a beta of 1.82.
Who Are BSGM's Competitors?
BSGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.77M | 61 |
| CBLL CeriBell, Inc. | $19.79 | +1.23% | $750.89M | 61 |
| CKMTF Carmat S.A. | $12.75 | -50.96% | $85.19M | 61 |
| ESTA Establishment Labs Holdings Inc. | $92.30 | +3.42% | $2.72B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BSGM's Key Strengths?
- Proprietary PURE EP system technology.
- Strategic collaboration with the Mayo Foundation.
- Research agreement with the University of Minnesota.
- Focus on improving signal acquisition during electrophysiology procedures.
What Are BSGM's Weaknesses?
- Small company with limited resources (5 employees).
- Reliance on a single product (PURE EP system).
- Limited market presence compared to larger competitors.
- Dependence on research collaborations for future growth.
What Could Drive BSGM Stock Higher?
- Expansion of PURE EP system adoption in hospitals and electrophysiology labs.
- Development of AI-driven diagnostic software in collaboration with the Mayo Foundation.
- Potential regulatory approvals for new products and therapies developed in collaboration with the University of Minnesota.
What Are the Key Risks for BSGM?
- Financial-distress signal — its Altman Z-Score of -4.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with broader product portfolios.
- Technological obsolescence of the PURE EP system.
- Dependence on research collaborations for future growth.
- Limited financial resources to support commercialization efforts.
What Are the Growth Opportunities for BSGM?
- Expansion of PURE EP System Adoption: BioSig can drive growth by increasing the adoption of its PURE EP system in hospitals and electrophysiology labs. The market for cardiac ablation technologies is projected to reach billions of dollars by 2030, driven by the increasing prevalence of atrial fibrillation. Securing contracts with major healthcare systems and demonstrating the clinical benefits of PURE EP could significantly increase market penetration. This expansion is an ongoing opportunity, contingent on successful clinical trials and effective marketing strategies.
- AI-Driven Diagnostics Development: The strategic collaboration with the Mayo Foundation to develop AI and machine learning software for the PURE EP system presents a significant growth opportunity. AI-driven diagnostics can enhance the system's capabilities, providing electrophysiologists with more detailed and accurate information during procedures. The market for AI in healthcare is rapidly expanding, and BioSig's collaboration positions it to capitalize on this trend. This is an ongoing opportunity, with potential for new product releases and revenue streams in the coming years.
- Research and Development of Novel Therapies: BioSig's research agreement with the University of Minnesota to develop novel therapies for sympathetic nervous system diseases represents a long-term growth opportunity. While still in the early stages, successful development of these therapies could diversify BioSig's product portfolio and address a broader range of medical conditions. This is an upcoming opportunity, with potential for clinical trials and regulatory approvals in the future.
- Strategic Partnerships and Acquisitions: BioSig can pursue strategic partnerships and acquisitions to expand its product offerings and market reach. Collaborating with or acquiring companies with complementary technologies or established distribution networks could accelerate growth and enhance BioSig's competitive position. This is an ongoing opportunity, with potential for deals to be announced at any time.
- Geographic Expansion: BioSig can expand its market presence by targeting new geographic regions. The market for electrophysiology devices is growing globally, particularly in developing countries with increasing healthcare infrastructure. Obtaining regulatory approvals and establishing distribution channels in these regions could significantly increase BioSig's revenue. This is an ongoing opportunity, with potential for expansion into new markets in the coming years.
What Opportunities Does BSGM Have?
- Expansion of PURE EP system adoption in hospitals and electrophysiology labs.
- Development of AI-driven diagnostic software in collaboration with the Mayo Foundation.
- Commercialization of novel therapies developed in collaboration with the University of Minnesota.
- Strategic partnerships and acquisitions to expand product offerings and market reach.
What Threats Does BSGM Face?
- Competition from established medical device companies with broader product portfolios.
- Need for regulatory approvals for new products and therapies.
- Potential for technological obsolescence.
- Dependence on research collaborations for future growth.
What Are BSGM's Competitive Advantages?
- Proprietary PURE EP system technology with signal processing capabilities.
- Strategic collaboration with the Mayo Foundation for AI-driven diagnostics.
- Research agreement with the University of Minnesota for novel therapies.
What Does BSGM Do?
BioSig Technologies, Inc., incorporated in 2009 and headquartered in Los Angeles, California, operates as a medical device company focused on improving the precision and efficiency of electrophysiology (EP) procedures. The company's core product is the PURE EP system, a signal processing platform designed to address challenges associated with signal acquisition during cardiac ablation procedures. The PURE EP system combines hardware and software to enable electrophysiologists to visualize and analyze intracardiac signals in real-time. This technology aims to overcome limitations that can slow down and disrupt cardiac catheter ablation procedures, particularly those targeting atrial fibrillation. BioSig collaborates with the University of Minnesota to develop therapies for sympathetic nervous system diseases. Additionally, the company has a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI and machine learning software solution for PURE EP systems, enhancing its diagnostic capabilities. BioSig's focus on innovation and strategic partnerships positions it within the evolving landscape of medical device technology.
What Products and Services Does BSGM Offer?
- Develops the PURE EP system, a signal processing platform for electrophysiology procedures.
- Focuses on improving the precision and efficiency of cardiac ablation procedures.
- Enhances intracardiac signal acquisition and diagnostic information for atrial fibrillation procedures.
- Collaborates with the Mayo Foundation to develop AI and machine learning software for PURE EP systems.
- Conducts research to develop novel therapies for sympathetic nervous system diseases.
- Addresses challenges associated with signal acquisition during cardiac ablation procedures.
How Does BSGM Make Money?
- Generates revenue through the sale of the PURE EP system.
- Potential future revenue streams from AI-driven diagnostic software developed in collaboration with the Mayo Foundation.
- Potential future revenue from novel therapies developed in collaboration with the University of Minnesota.
What Industry Does BSGM Operate In?
BioSig Technologies operates within the medical device industry, specifically targeting the electrophysiology (EP) market. This market is driven by the increasing prevalence of cardiac arrhythmias, such as atrial fibrillation, and the growing demand for minimally invasive ablation procedures. The competitive landscape includes established medical device companies with broader product portfolios. BioSig's focus on signal processing technology and AI-driven diagnostics positions it as a niche player within this market, aiming to improve the precision and efficiency of EP procedures.
Who Are BSGM's Key Customers?
- Hospitals and electrophysiology labs that perform cardiac ablation procedures.
- Electrophysiologists who use the PURE EP system to visualize and analyze intracardiac signals.
- Research institutions and universities involved in collaborative research and development efforts.
How BioSig Technologies, Inc. Is Valued
BioSig Technologies, Inc. carries a market capitalization of $191.13M, placing it in the micro-cap category. Relative to its peer group, BSGM's quantitative score of 61/100 is roughly in line with the peer average of 69/100.
Company Profile
BioSig Technologies, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Anthony Amato. BSGM has traded publicly since 2014.
F-Score 1/9Financial Health
BioSig Technologies, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.39 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project BioSig Technologies, Inc. revenue of about $59.1M for fiscal 2026, with EPS near $-0.17.
Net buyingInsider Activity
The most recent 8 insider filings for BioSig Technologies, Inc. break down as 0 sales and 8 purchases. On net that is roughly 1.2M shares acquired (about $0) — insiders putting money in tends to read as conviction.
BSGM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Insider buying has surged in recent weeks, indicating confidence from key stakeholders in the company's future.
- Recent community sentiment has turned positive, with discussions highlighting the potential of BioSig's innovative technology in the healthcare sector.
- The company has made strides in securing partnerships that may enhance its market position and credibility.
- Increased media coverage has spotlighted BioSig's advancements, contributing to a growing interest among retail investors.
Bear Case
- Despite positive sentiment, some analysts express concerns over the company's cash burn rate and its sustainability without additional funding.
- Community discussions reveal skepticism regarding the scalability of BioSig's technology in a competitive market.
- Recent earnings reports have raised questions about the company's ability to meet growth expectations in the near term.
- Market perception remains cautious, with some investors wary of the volatility associated with biotech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $13,000 | -$1M | -$0.01 |
Based on FMP financials and quantitative analysis
BSGM Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 13, 2020
BSGM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSGM.
Price Targets
Wall Street price target analysis for BSGM.
BSGM MoonshotScore
What does this score mean?
The MoonshotScore rates BSGM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anthony Amato
CEO
Anthony Amato serves as the CEO of BioSig Technologies, Inc. His background includes experience in managing and leading companies, though specific details on his career history and education are not provided. As CEO, Amato is responsible for overseeing the company's strategic direction, operations, and financial performance. He manages a small team of 5 employees. His leadership is crucial in guiding BioSig through its development and commercialization efforts.
Track Record: Under Anthony Amato's leadership, BioSig Technologies has focused on the development and commercialization of the PURE EP system. Key milestones include securing research collaborations with the University of Minnesota and the Mayo Foundation for Medical Education and Research. His strategic decisions have positioned BioSig as a player in the electrophysiology market, with a focus on improving signal acquisition during cardiac ablation procedures.
BioSig Technologies, Inc. Healthcare Stock: Key Questions Answered
What does BioSig Technologies, Inc. do?
BioSig Technologies, Inc. is a medical device company focused on developing and commercializing the PURE EP system, a signal processing platform designed to improve signal acquisition during electrophysiology procedures. The company's technology aims to enhance the precision and efficiency of cardiac ablation procedures, particularly those targeting atrial fibrillation. BioSig collaborates with research institutions like the Mayo Foundation and the University of Minnesota to develop AI-driven diagnostics and novel therapies, positioning itself as an innovator in the electrophysiology market.
What are the main risks for BSGM?
BioSig Technologies faces several risks, including competition from established medical device companies with broader product portfolios, the need for regulatory approvals for new products and therapies, and the potential for technological obsolescence. Additionally, the company's reliance on research collaborations for future growth and its limited financial resources pose challenges. Investors should carefully consider these risks before investing in BSGM.
What are the key factors to evaluate for BSGM?
BioSig Technologies, Inc. (BSGM) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does BSGM data refresh on this page?
BSGM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BSGM's recent stock price performance?
BioSig Technologies, Inc. (BSGM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary PURE EP system technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BSGM overvalued or undervalued right now?
Valuing BioSig Technologies, Inc. (BSGM) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BSGM?
Before investing in BioSig Technologies, Inc. (BSGM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BSGM to a portfolio?
Key strength of BioSig Technologies, Inc. (BSGM): Proprietary PURE EP system technology. Its MoonshotScore of 61/100 reflects solid quantitative fundamentals. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are limited and may not reflect the company's current performance.
- Analyst opinions are not available and should be sought from other sources.